Viva Biotech Holdings's book value per share for the quarter that ended in Dec. 2025 was €0.23.
During the past 12 months, Viva Biotech Holdings's average Book Value Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Viva Biotech Holdings was 181.10% per year. The lowest was -8.40% per year. And the median was 18.40% per year.
During the past 10 years, the highest P/B Ratio of Viva Biotech Holdings was 26.84. The lowest was 0.22. And the median was 1.00.
Good Sign:
Viva Biotech Holdings stock PB Ratio (=0.58) is close to 1-year low of 0.54.
Viva Biotech Holdings (FRA:VB0) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Viva Biotech Holdings Book Value per Share Related Terms
Viva Biotech Holdings Book Value per Share Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Book Value per Share of €0.23 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Viva Biotech Holdings and its competitors.
Is Viva Biotech Holdings' Book Value per Share too high?
Viva Biotech Holdings' current Book Value per Share is €0.23. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Book Value per Share compare to VRTX and REGN?
Viva Biotech Holdings' Book Value per Share of €0.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Book Value per Share is €0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 66.3% above its estimated fair value. The current Book Value per Share is €0.23. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Book Value per Share is €0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.13 is trading 66.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Book Value per Share: €0.23
GF Value™: €0.08 vs. price of €0.13 (66.3% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score
Get the complete analysis for FRA:VB0
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
